Bridging the gap in your Phase I clinical studies. 

Japan’s pharmaceutical market is the second largest in the world. Japan relies on the import of pharmaceutical goods to meet the needs of the country’s population. To capitalise upon these opportunities, drug developers must comply with the strict Pharmaceuticals and Medical Devices Agency (PMDA) regulations. Richmond Pharmacology’s expertise can help you bridge the gap in your next Phase I clinical study.

x

Learn about the bridging studies conducted at Richmond Pharmacology

A single centre study for Chiesi Pharmaceuticals. 16 Japanese and 16 Caucasian volunteers participated in cross over, bridging study for Chronic obstructive pulmonary disease. Read about our approach and the controls we introduced to reduce variability. Learn more here. Learn more here.

A cognitive function profile of a second generation antihistamine. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS) with 27 Japanese volunteers. Learn more here.

Why choose Richmond Pharmacology for your Bridging Study

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Expertise in PMDA criteria

We have conducted more than 100 ethnic bridging studies enabling us to build a trusted relationship with the PMDA.

Read more +

20,000 active 1st generation Japanese subjects

Our recruitment database is the largest in Europe with more than 20,000 active 1st generation Japanese subjects. 

Read more +

Short- and long-term residency periods

We can accommodate studies with short-term and long-term residency periods.

Read more +

Richmond Pharmacology's ethnic bridging studies will reduce the PMDA approval timeline and accelerate your time to market.

Fast track your global marketing approvals

Our expertise can help you accelerate your drug development timelines globally

Get in touch today

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event